We rank companies based on fund manager, research analyst and news sentiment
ATRI stock icon



About: Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.

Employees: 712

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

0.98% more ownership

Funds ownership: 64.71% [Q3] → 65.69% (+0.98%) [Q4]

1% more funds holding

Funds holding: 109 [Q3] → 110 (+1) [Q4]

7% less capital invested

Capital invested by funds: $471M [Q3] → $438M (-$32.7M) [Q4]

23% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 44

Research analyst outlook

We haven’t received any recent analyst ratings for ATRI.

Financial journalist opinion